Pushkal Garg Sells 3,022 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Pushkal Garg sold 3,022 shares of the stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $451.48, for a total value of $1,364,372.56. Following the transaction, the executive vice president directly owned 20,221 shares in the company, valued at approximately $9,129,377.08. This represents a 13.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Pushkal Garg also recently made the following trade(s):

• On Thursday, October 2nd, Pushkal Garg sold 2,937 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $452.05, for a total value of $1,327,670.85.
• On Tuesday, August 19th, Pushkal Garg sold 1,455 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $458.41, for a total value of $666,986.55.
• On Monday, August 18th, Pushkal Garg sold 1,396 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $453.27, for a total value of $632,764.92.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY opened at $456.35 on Friday. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. The firm has a market cap of $59.82 billion, a price-to-earnings ratio of -184.76 and a beta of 0.36. The business’s 50-day simple moving average is $441.57 and its 200-day simple moving average is $339.35. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $484.21.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.86. The business had revenue of $773.69 million for the quarter, compared to analyst estimates of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The firm’s revenue for the quarter was up 17.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analyst Ratings Changes

ALNY has been the subject of several recent analyst reports. Needham & Company LLC increased their target price on Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the company a “buy” rating in a research note on Thursday, July 31st. Chardan Capital increased their target price on Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Jefferies Financial Group increased their target price on Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the company a “buy” rating in a research note on Monday, July 7th. Raymond James Financial initiated coverage on Alnylam Pharmaceuticals in a research note on Wednesday, July 30th. They set an “outperform” rating and a $370.00 target price for the company. Finally, Citigroup increased their target price on Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the company a “buy” rating in a research note on Tuesday, September 2nd. Twenty-four analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $439.58.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several institutional investors have recently bought and sold shares of the business. Evelyn Partners Investment Management LLP boosted its stake in Alnylam Pharmaceuticals by 11.5% in the second quarter. Evelyn Partners Investment Management LLP now owns 290 shares of the biopharmaceutical company’s stock worth $95,000 after purchasing an additional 30 shares in the last quarter. Daiwa Securities Group Inc. boosted its stake in Alnylam Pharmaceuticals by 0.3% in the second quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock worth $4,220,000 after purchasing an additional 35 shares in the last quarter. Bayforest Capital Ltd boosted its stake in Alnylam Pharmaceuticals by 14.6% in the first quarter. Bayforest Capital Ltd now owns 306 shares of the biopharmaceutical company’s stock worth $83,000 after purchasing an additional 39 shares in the last quarter. MAI Capital Management boosted its stake in Alnylam Pharmaceuticals by 9.2% in the second quarter. MAI Capital Management now owns 488 shares of the biopharmaceutical company’s stock worth $159,000 after purchasing an additional 41 shares in the last quarter. Finally, Parkside Financial Bank & Trust boosted its stake in Alnylam Pharmaceuticals by 32.6% in the second quarter. Parkside Financial Bank & Trust now owns 179 shares of the biopharmaceutical company’s stock worth $58,000 after purchasing an additional 44 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.